Literature DB >> 24419369

New insights into the role of soluble guanylate cyclase in blood pressure regulation.

Emmanuel Buys1, Patrick Sips.   

Abstract

PURPOSE OF REVIEW: Nitric oxide (NO)-soluble guanylate cyclase (sGC)-dependent signaling mechanisms have a profound effect on the regulation of blood pressure (BP). In this review, we will discuss recent findings in the field that support the importance of sGC in the development of hypertension. RECENT
FINDINGS: The importance of sGC in BP regulation was highlighted by studies using genetically modified animal models, chemical stimulators/activators and inhibitors of the NO/sGC signaling pathway, and genetic association studies in humans. Many studies further support the role of NO/sGC in vasodilation and vascular dysfunction, which is underscored by the early clinical success of synthetic sGC stimulators for the treatment of pulmonary hypertension. Recent work has uncovered more details about the structural basis of sGC activation, enabling the development of more potent and efficient modulators of sGC activity. Finally, the mechanisms involved in the modulation of sGC by signaling gases other than NO, as well as the influence of redox signaling on sGC, have been the subject of several interesting studies.
SUMMARY: sGC is fast becoming an interesting therapeutic target for the treatment of vascular dysfunction and hypertension, with novel sGC stimulating/activating compounds as promising clinical treatment options.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24419369      PMCID: PMC4102174          DOI: 10.1097/01.mnh.0000441048.91041.3a

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   2.894


  73 in total

1.  Treatment of pulmonary hypertension caused by left heart failure with pulmonary arterial hypertension-specific therapies: lessons from the right and LEPHT.

Authors:  Lewis J Rubin
Journal:  Circulation       Date:  2013-06-17       Impact factor: 29.690

2.  Trial watch: Phase III success for first-in-class pulmonary hypertension drug.

Authors:  Man Tsuey Tse
Journal:  Nat Rev Drug Discov       Date:  2012-12       Impact factor: 84.694

3.  Orexin A regulates cardiovascular responses in stress-induced hypertensive rats.

Authors:  Fen Xiao; Meiyan Jiang; Dongshu Du; Chunmei Xia; Jin Wang; Yinxiang Cao; Linlin Shen; Danian Zhu
Journal:  Neuropharmacology       Date:  2012-11-09       Impact factor: 5.250

Review 4.  Sulfhydryl-dependent dimerization and cGMP-mediated vasodilatation.

Authors:  Dou Dou; Xiaoxu Zheng; Lei Ying; Liping Ye; Yuansheng Gao
Journal:  J Cardiovasc Pharmacol       Date:  2013-07       Impact factor: 3.105

5.  Riociguat for the treatment of chronic thromboembolic pulmonary hypertension.

Authors:  Hossein-Ardeschir Ghofrani; Andrea M D'Armini; Friedrich Grimminger; Marius M Hoeper; Pavel Jansa; Nick H Kim; Eckhard Mayer; Gerald Simonneau; Martin R Wilkins; Arno Fritsch; Dieter Neuser; Gerrit Weimann; Chen Wang
Journal:  N Engl J Med       Date:  2013-07-25       Impact factor: 91.245

6.  Riociguat for the treatment of pulmonary arterial hypertension.

Authors:  Hossein-Ardeschir Ghofrani; Nazzareno Galiè; Friedrich Grimminger; Ekkehard Grünig; Marc Humbert; Zhi-Cheng Jing; Anne M Keogh; David Langleben; Michael Ochan Kilama; Arno Fritsch; Dieter Neuser; Lewis J Rubin
Journal:  N Engl J Med       Date:  2013-07-25       Impact factor: 91.245

7.  Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study.

Authors:  Diana Bonderman; Stefano Ghio; Stephan B Felix; Hossein-Ardeschir Ghofrani; Evangelos Michelakis; Veselin Mitrovic; Ronald J Oudiz; Francis Boateng; Andrea-Viviana Scalise; Lothar Roessig; Marc J Semigran
Journal:  Circulation       Date:  2013-06-17       Impact factor: 29.690

8.  HNO/cGMP-dependent antihypertrophic actions of isopropylamine-NONOate in neonatal rat cardiomyocytes: potential therapeutic advantages of HNO over NO.

Authors:  Jennifer C Irvine; Nga Cao; Swati Gossain; Amy E Alexander; Jane E Love; Chengxue Qin; John D Horowitz; Barbara K Kemp-Harper; Rebecca H Ritchie
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-05-31       Impact factor: 4.733

9.  The effects of cyclic guanylate cyclase stimulation on right ventricular hypertrophy and failure alone and in combination with phosphodiesterase-5 inhibition.

Authors:  Asger Andersen; Jan M Nielsen; Sarah Holmboe; Mads D Vildbrad; Jens E Nielsen-Kudsk
Journal:  J Cardiovasc Pharmacol       Date:  2013-08       Impact factor: 3.105

10.  Thrombin has biphasic effects on the nitric oxide-cGMP pathway in endothelial cells and contributes to experimental pulmonary hypertension.

Authors:  Katrin F Nickel; Volker Laux; Rolf Heumann; Georges von Degenfeld
Journal:  PLoS One       Date:  2013-06-13       Impact factor: 3.240

View more
  9 in total

1.  Regulation of sGC via hsp90, Cellular Heme, sGC Agonists, and NO: New Pathways and Clinical Perspectives.

Authors:  Arnab Ghosh; Dennis J Stuehr
Journal:  Antioxid Redox Signal       Date:  2016-05-02       Impact factor: 8.401

2.  Nitric oxide-sensitive guanylyl cyclase stimulation improves experimental heart failure with preserved ejection fraction.

Authors:  Nicola Wilck; Lajos Markó; András Balogh; Kristin Kräker; Florian Herse; Hendrik Bartolomaeus; István A Szijártó; Maik Gollasch; Nadine Reichhart; Olaf Strauss; Arnd Heuser; Damian Brockschnieder; Axel Kretschmer; Ralf Lesche; Florian Sohler; Johannes-Peter Stasch; Peter Sandner; Friedrich C Luft; Dominik N Müller; Ralf Dechend; Nadine Haase
Journal:  JCI Insight       Date:  2018-02-22

Review 3.  Structure and Activation of Soluble Guanylyl Cyclase, the Nitric Oxide Sensor.

Authors:  William R Montfort; Jessica A Wales; Andrzej Weichsel
Journal:  Antioxid Redox Signal       Date:  2016-04-26       Impact factor: 8.401

4.  YC-1 alleviates bone loss in ovariectomized rats by inhibiting bone resorption and inducing extrinsic apoptosis in osteoclasts.

Authors:  Jin-Wen Wang; Chin-Bin Yeh; Shao-Jiun Chou; Kuo-Cheng Lu; Tzu-Hui Chu; Wei-Yu Chen; Jui-Lin Chien; Mao-Hsiung Yen; Tien-Hua Chen; Jia-Fwu Shyu
Journal:  J Bone Miner Metab       Date:  2017-10-05       Impact factor: 2.626

5.  Analysis of 200,000 Exome-Sequenced UK Biobank Subjects Implicates Genes Involved in Increased and Decreased Risk of Hypertension.

Authors:  David Curtis
Journal:  Pulse (Basel)       Date:  2021-07-05

6.  Genome-Wide microRNA Binding Site Variation between Extinct Wild Aurochs and Modern Cattle Identifies Candidate microRNA-Regulated Domestication Genes.

Authors:  Martin Braud; David A Magee; Stephen D E Park; Tad S Sonstegard; Sinead M Waters; David E MacHugh; Charles Spillane
Journal:  Front Genet       Date:  2017-01-31       Impact factor: 4.599

Review 7.  Maturation, inactivation, and recovery mechanisms of soluble guanylyl cyclase.

Authors:  Dennis J Stuehr; Saurav Misra; Yue Dai; Arnab Ghosh
Journal:  J Biol Chem       Date:  2021-01-26       Impact factor: 5.157

Review 8.  Structural Perspectives on the Mechanism of Soluble Guanylate Cyclase Activation.

Authors:  Elizabeth C Wittenborn; Michael A Marletta
Journal:  Int J Mol Sci       Date:  2021-05-21       Impact factor: 5.923

Review 9.  Current and Emerging Classes of Pharmacological Agents for the Management of Hypertension.

Authors:  Utkarsh Ojha; Sanjay Ruddaraju; Navukkarasu Sabapathy; Varun Ravindran; Pitchaya Worapongsatitaya; Jeesanul Haq; Raihan Mohammed; Vinod Patel
Journal:  Am J Cardiovasc Drugs       Date:  2021-12-08       Impact factor: 3.283

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.